A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil; OK-432 and Montanide; ISA-51 in patients with cancers expressing NY-ESO-1 antigen

Trial Profile

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil; OK-432 and Montanide; ISA-51 in patients with cancers expressing NY-ESO-1 antigen

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs Cancer vaccine NY-ESO-1 (Primary) ; Montanide ISA-51; Picibanil
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jul 2014 Status changed from recruiting to completed, as per University Hospital Medical Information Network - Japan.
    • 25 Jan 2012 Planned End Date changed from 1 Dec 2010 to 1 Dec 2012 as reported by University Hospital Medical Information Network - Japan.
    • 05 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top